Introduction
============

The incidence of Type 2 diabetes is increasing \[[@b1]\]. Over 80% of all people with Type 2 diabetes are overweight and over 50% are obese \[[@b2]\]. For patients with diabetes, obesity exacerbates metabolic problems, leading to increased morbidity and mortality \[[@b3]\]. Both Type 2 diabetes \[[@b4]\] and obesity \[[@b5]\] are associated with diminished health-related quality of life (QOL). Unfortunately, some effective glucose-lowering therapies may not only contribute to weight gain \[[@b6]\], but they may also lower treatment satisfaction and QOL \[[@b7]--[@b9]\].

Exenatide is a first-in-class glucagon-like peptide 1 receptor agonist approved for the treatment of Type 2 diabetes. Exenatide improves glycaemic and clinical parameters that could affect treatment satisfaction and QOL, including improved blood glucose control, decreased appetite and reduced weight \[[@b10],[@b11]\]. Significant benefits have been seen in patients taking exenatide twice daily (BID) and in those taking an exenatide once weekly (QW) formulation \[[@b10]--[@b12]\].

The current study is designed to assess the effects of exenatide BID and QW treatment on treatment satisfaction and QOL of patients with Type 2 diabetes managed with diet and exercise and/or oral glucose-lowering medications \[[@b13],[@b14]\]. Treatment satisfaction deserves attention because it may influence treatment adherence \[[@b15]\] and consequent clinical outcomes \[[@b15]--[@b17]\]. Quality of life is a critical outcome in its own right and a growing number of clinical trials now incorporate measures of health-related QOL as primary or secondary outcomes. We chose to use disease-specific measures for treatment satisfaction and QOL in the current study because such measures are generally considered more sensitive than generic measures to the predicted effects of clinical trial interventions \[[@b18]\].

In this study we attempted to answer the following questions: (i) does exenatide treatment affect diabetes treatment satisfaction and are changes in treatment satisfaction different for patients taking exenatide QW and BID?; (ii) does exenatide treatment affect weight-related QOL and are changes in weight-related QOL different for patients taking exenatide QW and BID?; (iii) do patients who switch from exenatide BID to exenatide QW experience further improvement in treatment satisfaction and QOL. In addition, we also assessed whether there are any differences in treatment satisfaction and weight-related QOL in those patients who did or did not report certain adverse events (AEs).

Research design and methods
===========================

Data source
-----------

Data for this study were obtained from a randomized, multi-centre, open-label study of subjects with Type 2 diabetes managed with diet and exercise and/or oral glucose-lowering medications. Two hundred and ninety-five patients received exenatide either once weekly (2 mg, QW) or twice daily (10 μg, BID) during weeks 1--30. The primary endpoint of the study was change in glycated haemoglobin (HbA~1c~) at 30 weeks. Following 30 weeks, 258 patients continued on to an open-ended treatment period with exenatide QW. Results of this study to 30 weeks and to 52 weeks for HbA~1c~, fasting plasma glucose, weight and adverse events are reported elsewhere \[[@b13],[@b14]\]. Briefly, the exenatide QW group showed greater improvements in HbA~1c~ (−1.9 vs. −1.5% for exenatide BID at 30 weeks; *P* = 0.0023) and fasting plasma glucose (−2.3 vs. −1.4 mmol/l for exenatide BID; *P* \< 0.0001), with similar levels of weight loss and adverse events. There was no major hypoglycaemia in either exenatide regimen. One patient who received exenatide QW with non-sulphonylurea background therapy had an episode of minor hypoglycaemia. Most minor hypoglycaemia occurred in patients using concomitant sulphonylurea (eight of 55 receiving exenatide QW and eight of 54 receiving exenatide BID).

The presence of an AE of nausea or vomiting was defined as having at least one treatment-emergent adverse event (TEAE) during the 30-week treatment period; two subjects in each treatment arm withdrew from the study as a result of nausea or vomiting. The presence of injection site reactions was defined as having at least one TEAE during the 30-week comparison period with Medical Dictionary for Regulatory Activities (MedDRA) preferred terms comprising any of the following 'injection site' terms: bruising, erythema, haematoma, haemorrhage, induration, irritation, nodule, pain, pruritus, rash, swelling or urticaria.

Patient-reported outcome (PRO) instruments
------------------------------------------

Patients completed a measure of diabetes treatment satisfaction, the Diabetes Treatment Satisfaction Questionnaire status version (DTSQ-s) and a measure of QOL, the Impact of Weight on Quality of Life---Lite (IWQOL-Lite), at baseline and weeks 30 and 52. Patients were asked to complete the PRO instruments at the beginning of their clinic visit, prior to any procedures. Patients who terminated their participation prior to week 30 were asked to complete the study questionnaires as part of their early termination assessment.

Diabetes Treatment Satisfaction Questionnaire (DTSQ)
----------------------------------------------------

Diabetes treatment satisfaction was assessed with the Diabetes Treatment Satisfaction Questionnaire---status version (DTSQ-s) \[[@b19]\].

The DTSQ-s contains eight items assessing: overall treatment satisfaction, treatment convenience and flexibility, satisfaction with understanding of diabetes, willingness to continue present treatment and to recommend it to others and frequency of unacceptably high and unacceptably low blood glucose levels. Response categories for all items are on a 7-point Likert scale. DTSQ-s scores range from 0 (e.g. very dissatisfied) to 6 (e.g. very satisfied). All items except perceived hypoglycaemia and hyperglycaemia items are summed to produce a total treatment satisfaction score. The DTSQ-s total treatment satisfaction scores range from 0 to 36. Higher scores on the DTSQ-s total score indicate higher satisfaction. The perceived frequency of hyperglycaemia and hypoglycaemia items are scored separately; lower scores on these two items represent better perceived blood glucose control. Missing data at each assessment were imputed as the average of the valid item values.

Weight-related quality of life (IWQOL-Lite)
-------------------------------------------

The impact of weight-related QOL was assessed with the IWQOL-Lite, a 31-item self-report measure assessing weight-related QOL in five domains: physical function, self-esteem, sexual life, public distress and work \[[@b5]\]. The IWQOL-Lite has demonstrated robust psychometric properties in obese persons with and without diabetes \[[@b20]\]. IQWOL-Lite scores (total score and separate scores for each of the five domains) range from 0 to 100, with 0 representing the worst outcome and 100 representing the best. Raw scores for each of the IWQOL-Lite scales were computed only if at least 50% of the items for that scale were answered, and the total score was computed only if at least 75% of all items were answered. Missing data at each follow-up assessment were imputed as the average of the valid item values.

Statistical analysis
--------------------

The intent-to-treat population, defined as all randomized subjects who received at least one injection of study medication (exenatide), was used. All tests of treatment effects were conducted at a two-sided significance level of 0.05. There was no adjustment in significance levels for multiple comparisons. The pre-specified primary analysis of PROs was to compare the treatment effects between groups at week 30.

[ancova]{.smallcaps} \[adjusted for baseline DTSQ-s or IWQOL-Lite score, HbA~1c~ strata (screening HbA~1c~ \< 9.0 vs. ≥ 9.0%), treatment group and sulphonylurea use at screening (Yes vs. No)\] was used to estimate least squares (LS) mean group changes from baseline to week 30. Two-sided 95% confidence intervals (CIs) were computed for changes at week 30. [ancova]{.smallcaps} used last observation carried forward (LOCF); the last available post-baseline observation (including Early Termination) was used to impute missing data for the PRO measures, as long as the subject had PRO data for at least one post-baseline (including Early Termination) visit.

LS mean change and the within-group standard deviation of change were used to calculate standard response mean (SRM) effect sizes (i.e. measure the magnitude of treatment effect for each group) \[[@b21]\]. Effect sizes of small, medium and large are indicated by cut-offs of 0.20, 0.50 and 0.80, respectively \[[@b21],[@b22]\].

Pairwise Student's*t*-tests for correlated outcomes were used to estimate change in DTSQ-s and IWQOL-Lite from week 30 to week 52 for each treatment group. Change within the group switching from exenatide BID to QW provides a direct test of the effect of changing exenatide regimens.

Results
=======

Baseline characteristics
------------------------

The ITT population comprised 295 patients (148 exenatide QW, 147 exenatide BID). Demographic and baseline clinical variables are summarized in [Table 1](#tbl1){ref-type="table"}. Mean age of study participants was 55 years, slightly more than half were male and the majority of the participants were white, with a mean body mass index (BMI) of 35 kg/m^2^, a mean HbA~1c~ of 8.3% and mean diabetes duration of 6--7 years. On entry to the study, participants were treated either with diet and exercise alone or with one or more of a variety of oral glucose-lowering agents. There were no statistically significant differences between the two treatment groups for any of these characteristics \[[@b13]\] nor for baseline PRO scores.

###### 

Baseline demographic and clinical characteristics of subjects with Type 2 diabetes participating in a 30-week, randomized, multi-centre, open-label study of exenatide treatment

  Characteristic                                            Exenatide QW (*n* = 148)   Exenatide BID (*n* = 147)
  --------------------------------------------------------- -------------------------- ---------------------------
  Age (years), mean ± [sd]{.smallcaps}                      55 ± 10                    55 ± 10
  Gender, *n* (%)                                                                      
  Male                                                      82 (55)                    75 (51)
  Female                                                    66 (45)                    72 (49)
  Race/ethnicity, *n* (%)                                                              
  White                                                     123 (83)                   107 (73)
  Black                                                     9 (6)                      19 (13)
  Hispanic                                                  16 (11)                    20 (14)
  Asian                                                     0 (0)                      1 (1)
  Weight (kg), mean ± [sd]{.smallcaps}                      102 ± 19                   102 ± 21
  BMI (kg/m^2^), mean ± [sd]{.smallcaps}                    35 ± 5                     35 ± 5
  HbA~1c~ (%), mean ± [sd]{.smallcaps}                      8.3 ± 1.0                  8.3 ± 1.0
  Duration of diabetes (years), mean ± [sd]{.smallcaps}     7 ± 6                      6 ± 5
  Diabetes management at screening, *n* (%)                                            
  Diet/exercise                                             21 (14)                    23 (16)
  Metformin only                                            56 (38)                    50 (34)
  Sulphonylureas only                                       6 (4)                      10 (7)
  Thiazolidinediones only                                   2 (1)                      7 (5)
  Metformin + sulphonylureas                                43 (29)                    39 (27)
  Metformin + thiazolidinediones                            13 (9)                     11 (8)
  All metformin[\*](#tf1-1){ref-type="table-fn"}            114 (77)                   102 (69)
  All sulphonylureas[\*](#tf1-1){ref-type="table-fn"}       55 (37)                    54 (37)
  All thiazolidinediones[\*](#tf1-1){ref-type="table-fn"}   22 (15)                    25 (17)

Includes specified agent alone or in combination.

BID, twice daily; BMI, body mass index; HbA~1c~, glycated haemoglobin; QW, once weekly; [sd]{.smallcaps}, standard deviation.

Effect of exenatide treatment on diabetes treatment satisfaction
----------------------------------------------------------------

At week 30, total DTSQ-s scores had improved significantly from baseline in both treatment arms (*P* \< 0.001), with significant improvement for all specific items, except for perceived hypoglycaemia frequency in the exenatide QW arm, and significant improvement for all items, except perceived hypoglycaemia frequency and treatment convenience in the exenatide BID arm. Effect sizes for change in DTSQ-s total scores at week 30 were 0.84 for exenatide QW compared with 0.64 for exenatide BID. Statistically significant improvements in total treatment satisfaction for both treatment regimens met the conventional criterion for clinical meaningfulness \[≥ 0.5 standard deviation ([sd]{.smallcaps}) units\], as assessed by the standardized response mean \[[@b22]\]. Effect sizes for change in DTSQ-s individual items from baseline to week 30 ranged from 0.06 to 1.25 in the exenatide QW group and 0.11 to 0.87 in the exenatide BID group.

At week 30, between-treatment group differences in DTSQ-s total scores were not statistically significant (*P* = 0.09), but treatment satisfaction did improve more in the exenatide QW arm for perceived hyperglycaemia frequency (*P* = 0.03) and willingness to continue current treatment (*P* = 0.01).

From week 30 to week 52 ([Table 3](#tbl3){ref-type="table"}), patients who switched from exenatide BID to exenatide QW experienced significantly improved total treatment satisfaction (*P* = 0.037), treatment convenience (*P* = 0.003), treatment flexibility (*P* = 0.012) and satisfaction with continuing treatment (*P* = 0.048). Patients who continued with exenatide QW experienced significantly improved satisfaction with treatment convenience (*P* = 0.006) and treatment flexibility (*P* = 0.025) from week 30 to week 52. All significant improvements in treatment satisfaction from baseline to week 30 remained significant in comparisons from baseline to week 52.

###### 

Change (± [sd]{.smallcaps}) from week 30 to week 52 in Diabetes Treatment Satisfaction Questionnaire---Status version (DTSQ-s) and Impact of Weight on Quality of Life---Lite (IWQOL-Lite) among subjects with Type 2 diabetes participating in a randomized, open-label study of exenatide treatment (intent-to-treat population)

                                         Exenatide QW   Exenatide BID → QW                                       
  -------------------------------------- -------------- -------------------------------------------------- ----- --------------------------------------------------
  DTSQ                                                                                                           
  DTSQs total score                      119            0.65 ± 3.8                                         123   1.16 ± 6.1[\*](#tf3-1){ref-type="table-fn"}
  Treatment satisfaction---current       119            0.10 ± 0.77                                        123   0.01 ± 1.2
  Perceived frequency high blood sugar   119            −0.04 ± 1.9                                        123   −0.15 ± 1.8
  Perceived frequency low blood sugar    119            −0.18 ± 1.4                                        123   −0.21 ± 1.4
  Treatment convenience                  119            0.30 ± 1.2[\*\*](#tf3-2){ref-type="table-fn"}      123   0.42 ± 1.6[\*\*](#tf3-2){ref-type="table-fn"}
  Treatment flexibility                  119            0.24 ± 1.2[\*](#tf3-1){ref-type="table-fn"}        122   0.39 ± 1.7[\*](#tf3-1){ref-type="table-fn"}
  Understanding of diabetes              119            0.06 ± 0.94                                        123   0.04 ± 1.2
  Treatment recommend                    119            −0.05 ± 0.94                                       123   0.07 ± 1.1
  Treatment satisfaction---continue      119            −0.01 ± 0.93                                       123   0.24 ± 1.3[\*](#tf3-1){ref-type="table-fn"}
  IWQOL-Lite                                                                                                     
  IWQOL-Lite total score                 120            0.36 ± 7.1                                         127   1.44 ± 8.7
  Physical function                      121            0.08 ± 9.5                                         128   2.13 ± 11.5[\*](#tf3-1){ref-type="table-fn"}
  Self-esteem                            121            0.83 ± 10.9                                        128   1.12 ± 11.5
  Sexual life                            118            0.64 ± 17.3                                        124   0.91 ± 15.2
  Public distress                        120            6.96 ± 13.2[\*\*\*](#tf3-3){ref-type="table-fn"}   127   5.04 ± 11.2[\*\*\*](#tf3-3){ref-type="table-fn"}
  Work                                   119            0.42 ± 9.8                                         125   1.10 ± 11.2

*P* ≤ 0.05;

*P* \< 0.01;

*P* \< 0.001.

Number of subjects with week 30 and week 52 scores.

BID, twice daily; QW, once weekly; [sd]{.smallcaps}, standard deviation.

Effects of exenatide treatment on weight-related quality of life
----------------------------------------------------------------

At week 30 ([Table 2](#tbl2){ref-type="table"}), IWQOL-Lite total scores and all separate domain scores had increased significantly in both treatment arms (all *P* \< 0.001). Effect sizes for change in IWQOL-Lite total score at week 30 were 0.96 for the exenatide QW and 0.82 for the exenatide BID group. Statistically significant improvements in total treatment satisfaction for both treatment regimens met the conventional criterion for clinical meaningfulness (≥ 0.5 [sd]{.smallcaps} units), as assessed by the standardized response mean \[[@b21],[@b22]\]. There were no statistically significant differences in weight-related QOL between treatment arms.

###### 

Change (± [se]{.smallcaps})[†](#tf2-3){ref-type="table-fn"} from baseline to week 30 in Diabetes Treatment Satisfaction Questionnaire---Status version (DTSQ-s) and Impact of Weight on Quality of Life---Lite (IWQOL-Lite) among subjects with Type 2 diabetes participating in a randomized, multi-centre, open-label study of exenatide treatment (intent-to-treat population)

                                         Exenatide QW   Exenatide BID                                                                                                                                                                     
  -------------------------------------- -------------- --------------- --------------------------------------------------- -------------- ------ ----- ------- --------------------------------------------------- -------------- ------ ------
  DTSQ                                                                                                                                                                                                                                    
  DTSQ-s total score                     137            31.17           5.17 ± 0.54[\*\*\*](#tf2-2){ref-type="table-fn"}    4.11, 6.23     0.84   142   29.97   3.97 ± 0.53[\*\*\*](#tf2-2){ref-type="table-fn"}    2.94, 5.01     0.64   0.09
  Treatment satisfaction---current       130            5.29            1.29 ± 0.12[\*\*\*](#tf2-2){ref-type="table-fn"}    1.06, 1.52     0.94   136   5.11    1.11 ± 0.11[\*\*\*](#tf2-2){ref-type="table-fn"}    0.89, 1.33     0.87   0.23
  Perceived frequency high blood sugar   130            1.95            −1.86 ± 0.15[\*\*\*](#tf2-2){ref-type="table-fn"}   −2.16, −1.55   1.09   136   2.39    −1.42 ± 0.15[\*\*\*](#tf2-2){ref-type="table-fn"}   −1.71, −1.12   0.81   0.03
  Perceived frequency low blood sugar    131            0.92            0.08 ± 0.12                                         −0.15, 0.31    0.06   136   0.98    0.14 ± 0.11                                         −0.08, 0.37    0.11   0.69
  Treatment convenience                  130            4.79            0.25 ± 0.13[\*](#tf2-1){ref-type="table-fn"}        0.00, 0.50     0.17   136   4.68    0.14 ± 0.13                                         −0.11, 0.39    0.09   0.52
  Treatment flexibility                  130            4.91            0.49 ± 0.13[\*\*\*](#tf2-2){ref-type="table-fn"}    0.23, 0.75     0.33   135   4.69    0.27 ± 0.13[\*](#tf2-1){ref-type="table-fn"}        0.01, 0.52     0.18   0.19
  Understanding of diabetes              132            4.95            0.50 ± 0.10[\*\*\*](#tf2-2){ref-type="table-fn"}    0.29, 0.70     0.44   136   5.02    0.56 ± 0.10[\*\*\*](#tf2-2){ref-type="table-fn"}    0.36, 0.76     0.48   0.63
  Treatment recommend                    130            5.59            0.98 ± 0.10[\*\*\*](#tf2-2){ref-type="table-fn"}    0.79, 1.17     0.86   136   5.44    0.83 ± 0.10[\*\*\*](#tf2-2){ref-type="table-fn"}    0.64, 1.01     0.71   0.23
  Treatment satisfaction---continue      130            5.46            1.43 ± 0.13[\*\*\*](#tf2-2){ref-type="table-fn"}    1.18, 1.68     1.25   136   5.02    0.99 ± 0.12[\*\*\*](#tf2-2){ref-type="table-fn"}    0.75, 1.24     0.85   0.01
  IWQOL-Lite                                                                                                                                                                                                                              
  IWQOL-Lite total score                 143            82.74           10.23 ± 0.89[\*\*\*](#tf2-2){ref-type="table-fn"}   8.48, 11.97    0.96   143   81.13   8.61 ± 0.88[\*\*\*](#tf2-2){ref-type="table-fn"}    6.88, 10.34    0.82   0.16
  Physical function                      126            77.72           12.06 ± 1.20[\*\*\*](#tf2-2){ref-type="table-fn"}   9.67, 14.45    0.89   130   75.21   9.55 ± 1.21[\*\*\*](#tf2-2){ref-type="table-fn"}    7.17, 11.92    0.69   0.11
  Self-esteem                            126            80.47           13.60 ± 1.31[\*\*\*](#tf2-2){ref-type="table-fn"}   11.02, 16.18   0.83   130   80.58   13.71 ± 1.30[\*\*\*](#tf2-2){ref-type="table-fn"}   11.14, 16.28   0.85   0.95
  Sexual life                            123            84.09           7.34 ± 1.51[\*\*\*](#tf2-2){ref-type="table-fn"}    4.36, 10.32    0.44   127   83.7    6.95 ± 1.50[\*\*\*](#tf2-2){ref-type="table-fn"}    4.00, 9.89     0.41   0.84
  Public distress                        125            89.83           6.05 ± 1.00[\*\*\*](#tf2-2){ref-type="table-fn"}    4.07, 8.02     0.52   130   87.85   4.07 ± 1.00[\*\*\*](#tf2-2){ref-type="table-fn"}    2.11, 6.03     0.36   0.13
  Work                                   124            91.14           8.17 ± 1.13[\*\*\*](#tf2-2){ref-type="table-fn"}    5.95, 10.38    0.65   129   88.79   5.81 ± 1.12[\*\*\*](#tf2-2){ref-type="table-fn"}    3.61, 8.01     0.46   0.11

*P* ≤ 0.05;

*P* \< 0.001.

Data are least squares (LS) mean changes.

Number of subjects with a post-randomization score.

Standardized response mean.

Comparisons between treatment groups.

BID, twice daily; CI, confidence interval; QW, once weekly; [se]{.smallcaps}, standard error.

Patients who switched from exenatide BID to QW at week 30 ([Table 3](#tbl3){ref-type="table"}) reported further significant improvement for the physical function (*P* = 0.04) and public distress (*P* \< 0.001) domains. Patients who continued on QW improved significantly from week 30 to week 52 for public distress (*P* \< 0.001). All significant improvements in QOL from baseline to week 30 remained significant in comparisons from baseline to week 52.

Potential mediators/moderators of effects on treatment satisfaction and quality of life
---------------------------------------------------------------------------------------

There was no significant difference in total treatment satisfaction in the 89 subjects who experienced nausea and/or vomiting vs. the 190 who did not (*P* = 0.97) and the effect did not differ across treatment arms (*P* = 0.59). Treatment satisfaction was also similar for patients who did (*n* = 61) or did not (*n* = 218) experience an injection site reaction (*P* = 0.41); the effect did not differ across treatment arms (*P* = 0.44).

There was no significant difference in overall weight-related QOL in subjects who did and did not experience nausea (*P* = 0.56), a common side effect of exenatide therapy, and the effect did not differ across treatment arms (*P* = 0.42). There was also no significant difference in weight-related quality of life in subjects who did and did not experience an injection site reaction (*P* = 0.70); the effect did not differ across treatment arms (*P* = 0.49).

Discussion
==========

In this study, treatment satisfaction and weight-related QOL were significantly improved with the addition of exenatide to treatment with diet, exercise and/or oral glucose-lowering medication. Benefits were substantial and were manifest across the full range of dimensions studied. Treatment satisfaction and weight-related QOL improved significantly from baseline to week 30 in both treatment arms, with no significant difference between treatment arms in total treatment satisfaction or QOL, but a greater improvement in the exenatide QW arm in perceived hyperglycaemia frequency and willingness to continue current treatment. All improvements were sustained from week 30 to week 52 among patients who continued with exenatide QW; moreover, there were significant improvements in treatment convenience and treatment flexibility. In addition, patients who switched from exenatide BID to exenatide QW at week 30 reported significantly improved total treatment satisfaction, treatment convenience, treatment flexibility and satisfaction with continuing treatment at week 52.

This study is the first to assess treatment satisfaction and quality of life in patients treated with exenatide QW and our findings suggest that both exenatide QW and exenatide BID are associated with statistically significant and clinically meaningful improvements (i.e. moderate or greater effect sizes) in these important patient-reported outcomes. The fact that improvements in treatment satisfaction and quality of life were maintained over 52 weeks suggests that these effects are durable and the fact that participants continued to prefer exenatide to their pre-study treatment regimen suggests that patients may be willing to continue to manage their Type 2 diabetes with exenatide treatment. Sustained use in the general population of patients with diabetes could bring many patients the benefits associated with exenatide treatment in clinical trials, including improved blood glucose control and significantly reduced weight \[[@b10]--[@b14]\].

We found some evidence that use of exenatide QW was associated with greater improvements in treatment satisfaction than use of exenatide BID. At week 30, patients in the exenatide QW arm were significantly more likely than those in the exenatide BID arm to be willing to continue taking the study medication and, between weeks 30 and 52, patients who switched to exenatide QW improved on a number of treatment satisfaction measures, including total satisfaction and willingness to continue treatment. This suggests that acceptance of exenatide QW may be even greater than that for exenatide BID, perhaps because of ease of use and less frequent administration regimen of once weekly. Another possible reason for the greater acceptance of exenatide QW is the greater improvement in glucose control \[[@b13],[@b14]\]; notably, reduction in the perceived frequency of hyperglycaemia was the specific benefit for which exenatide QW had the largest advantage over exenatide BID.

The common adverse effects of treatment experienced in this study (nausea/vomiting or injection site reactions), which were more common in the exenatide BID group \[[@b13],[@b14]\], did not affect patients' treatment satisfaction or quality of life. This suggests that these adverse effects were not severe enough to affect patients' perceptions of the study medications.

Study strengths
---------------

Strengths of the study include the substantial number of participants and the relatively long duration of the trial. In addition, the study outcomes, treatment satisfaction and quality of life were assessed using validated questionnaires likely to be sensitive to the established clinical effects of the study medication. The study design allowed us to assess not only the effects of each formulation of the study medication in patients who had never taken exenatide, but also the effects of switching to exenatide QW in patients who had been taking exenatide BID. Finally, we were able to assess the effects of commonly reported medication side effects on treatment satisfaction and quality of life.

Study limitations
-----------------

Study design limitations include the fact that there was no placebo comparator group that continued with their pre-study medications to assess placebo effects and there was no crossover from exenatide QW to exenatide BID to assess order effects. These features would have required a larger and longer-term study. A longer-term follow-up of exenatide QW would have been beneficial, but the design did permit 52 weeks of patient experience which is the longest term study of exenatide QW to date; 3.5-year follow-up data on exenatide BID has already been published \[[@b23]\]. Also, the participation of ethnic minorities was rather low, limiting the generalizability of the study findings to these groups. Finally, it would have been useful to examine outcomes for psychological well-being and diabetes distress.

Implications for future research
--------------------------------

While the results suggest that exenatide BID and QW are both viable treatment strategies, it remains to be seen whether the different medications are preferred by different patient subgroups. Systematic evaluation of patient differences that account for alternative preferences should be pursued.

Clinical implications
---------------------

Exenatide treatment has been associated with important clinical benefits, including improved glucose control and weight loss \[[@b10],[@b11],[@b13],[@b14]\]. Patients previously treated with diet and exercise and/or oral medication reported improved weight-related QOL, higher satisfaction with the study medication than their previous therapy and more willingness to continue taking the medication and recommend it to others. They also reported that the study medication was more flexible and convenient, despite the fact that it involved taking injections. Moreover, the recognized side effects of exenatide treatment---nausea/vomiting and injection site reactions---did not affect treatment satisfaction and quality of life in this study, suggesting that these effects might not be a barrier to patients' accepting treatment with these medications.

Finally, patients switching from exenatide BID to exenatide QW reported additional improvements in treatment convenience and overall treatment satisfaction. Not surprisingly, patients seem to prefer taking a medication once a week rather than twice a day. This simpler regimen could improve treatment adherence in real-world clinical settings \[[@b24]\].

In combination with earlier findings from this study \[[@b13],[@b14]\], our results indicate it is possible for patients treated with diet/exercise and/or oral agents to initiate exenatide therapy with potential benefits in both clinical efficacy and patient-reported outcomes directly related to treatment adherence.
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AE

:   adverse event

BID

:   twice daily

DTSQ

:   Diabetes Treatment Satisfaction Questionnaire

HbA~1c~

:   glycated haemoglobin

IWQOL-Lite

:   Impact of Weight on Quality of Life---Lite

LS

:   least squares

PRO

:   patient-reported outcome

QOL

:   quality of life

QW

:   once weekly

[sd]{.smallcaps}

:   standard deviation

TEAE

:   treatment-emergent adverse event
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